LONDON (dpa-AFX) - Aratana Therapeutics Inc.'s (PETX) Entyce has been
approved by the FDA's Center for Veterinary Medicine for appetite stimulation in
dogs. The company intends to commercially launch the product in conjunction with
NEW YORK CITY (dpa-AFX) - BioTelemetry Inc. (BEAT) has reported revenue of
$48.6 million for the first quarter ended March 31, 2016, which is the highest
quarterly revenue in the company's history, and a 12% increase over prior year.
WASHINGTON (dpa-AFX) - Aratana Therapeutics Inc. (PETX) has filed a
Marketing Authorization Application with the European Medicines Agency for
Galliprant, intended to treat pain and inflammation in dogs with osteoarthritis.
The EMA has started...
Shares of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) lost nearly half of its value Wednesday morning after the company disclosed it received a "Refusal to File" letter from the U.S. Food and Drug Administration.
The "Refusal to File" letter...
WASHINGTON (dpa-AFX) - Shares of Acasti Pharma Inc. (ACST) surged more than
56% on Wednesday on encouraging response from the FDA for the proposed 505(b)(2)
pathway for CaPre clinical development.
Last September, the company reported successful...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Catalyst Pharmaceutical Partners (CPRX):